A leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop and manufacture biologics from concept to commercial manufacturing.

Technology platforms that span the entire drug discovery to manufacturing spectrum, including novel, industry-leading systems and tools for continuous manufacturing and the development of cell lines, bispecific antibodies, and antibody drug conjugates. 

One-stop discovery platform for the generation, screening, selection, optimization, characterization and production of high potency, novel antibody therapeutics, ADCs and other biologics from target identification to final lead preclinical candidate (PCC) selection.

Unparalleled capacities and expertise for the discovery, development and cGMP manufacture of biologics from mammalian cell culture. We offer integrated programs utilizing 6 discovery platforms, one of the largest global CMC development teams and an extensive drug substance and drug product supply chain network across multiple countries.

Comprehensive CMC development and cGMP manufacturing microbial fermentation platform. 

E. coli and yeast-based expression systems for the production of plasmid DNA and recombinant proteins. 

Global, one-stop CMC development and cGMP manufacturing for viral vaccines

Comprehensive and integrated discovery, CMC development and cGMP manufacturing platform for Antibody Drug Conjugates (ADCs) and other bioconjugates.  Leading ADC engineering technologies, expertise and quality systems to ensure right-first-time  project execution.

WuXi Biologics provides extensive expertise and high-quality biosafety testing under EMA, ISO (CNAS) and CMA certified laboratories and full analytical development and QC labor atories approved by U.S. FDA, EMA and NMPA.

World-class quality systems approved by the U.S. FDA, EMA and the first organization in China to be approved for production of a commercial bio therapeutic.